We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Did you mean safe weight loss?
Resources to support the commissioning and delivery of tier 2 behavioural weight management services for children, families and adults.
Information on cryptosporidium including sources and routes of transmission, symptoms, and general hygiene advice to minimise the spread.
This article presents findings from a systematic review and meta-analysis
From coughs and sneezes to mental health apps, these tips from the MHRA will help you stay safe during the festive season and beyond
Semaglutide is the first weight loss drug approved in the UK as a preventative treatment for those with established cardiovascular disease
The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding healthcare professionals to ensure patients are aware of the known side effects of glucagon-like peptide-1 (GLP-1) receptor agonists.
Get quick, tailored answers with GOV.UK’s experimental AI chat
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).